MikkaelA.SekeresMD

PubMed

• 65 citations
  Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
  Mikkael A Sekeres, Justin Taylor
  JAMA. 2022-09-06
• 93 citations
  The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
  Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
  Blood Advances. 2018-07-24
• 48 citations
  Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
  Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag, Philippe Rousselot, Guillermo Garcia-Manero
  Clinical Lymphoma, Myeloma & Leukemia. 2013-10-01

Journal Articles

• Germline Loss of Function SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes  
  Samuel Li, Mikkael A Sekeres, Jaroslaw P Maciejewski, Rabi Hanna, Blood
• Relative Survival Following Response to 7 + 3 Versus Azacytidine Is Similar in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes: An Analysis of Four SWOG...  
  Sucha Nand, Mikkael A Sekeres, Nature
• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Join now to see all

Abstracts/Posters

• Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuri
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patient...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Determinants of Fitness for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in AdultsClinically Relevant Abstract
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Meeting Tips: Giving a Scientific Presentation, Being a Good Discussant and Asking a Question in the Aisle 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Late-Breaking Abstracts Session 
  60th American Society of Hematology Annual Meeting - 12/4/2018
• The Story Is the Story: Using Narrative Medicine to Cure Disease 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Blood Drops: Telling It Like It Is: Essays About Medicine 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Watching My Patient Die, Remotely 
  American Society of Hematology (ASH), New York, New York - 2/3/2012
• Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic mye... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Resolutions of a Cancer Doctor 
  American Society of Hematology (ASH), Austin, Texas - 1/20/2012
• Resolutions of a Cancer Doctor 
  American Society of Hematology (ASH), Las Vegas, Nevada - 1/27/2012
• Join now to see all